AR095499A1 - ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b - Google Patents

ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b

Info

Publication number
AR095499A1
AR095499A1 ARP140101104A ARP140101104A AR095499A1 AR 095499 A1 AR095499 A1 AR 095499A1 AR P140101104 A ARP140101104 A AR P140101104A AR P140101104 A ARP140101104 A AR P140101104A AR 095499 A1 AR095499 A1 AR 095499A1
Authority
AR
Argentina
Prior art keywords
seq
amino acids
sequence
antibody comprises
antibody
Prior art date
Application number
ARP140101104A
Other languages
English (en)
Inventor
Hermiston Terry
Jin Ye
Murphy John
Dr Strerath Michael
Myles Timothy
Dr Dittmer Frank
Dr Gritzan Uwe
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095499(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AR095499A1 publication Critical patent/AR095499A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

Reivindicación 1: Un anticuerpo monoclonal capaz de unirse al complejo antitrombina (b)-heparina (ATbH), en el que la cadena pesada de dicho anticuerpo comprende: una secuencia CDR1 de aminoácidos 31 a 35 (AYRMG) de SEC ID Nº 2, una secuencia CDR2 de aminoácidos 50 a 66 (RIYSSGGRTRYADSVKG) de SEC ID Nº 2 y una secuencia CDR3 de aminoácidos 97 a 114 (AREKASDLSGSFSEALDY) de SEC ID Nº 2; y en el que la cadena ligera de dicho anticuerpo comprende: una secuencia CDR1 de aminoácidos 24 a 34 (QGDSLRSYYAS) de SEC ID Nº 1, una secuencia CDR2 de aminoácidos 50 a 56 (GKNNRPS) de SEC ID Nº 1 y una secuencia CDR3 de aminoácidos 89 a 99 (NSRDSSGNHLV) de SEC ID Nº 1. Reivindicación 20: Una composición farmacéutica que comprende una cantidad terapéuticamente eficaz del anticuerpo monoclonal de una cualquiera de las reivindicaciones 1 - 14 y un vehículo farmacéuticamente aceptable. Reivindicación 21: Un procedimiento para tratar una deficiencia o defecto genético o adquirido en la coagulación que comprende administrar una cantidad terapéuticamente eficaz de una composición farmacéutica de una cualquiera de las reivindicaciones 1 - 14 a un paciente. Reivindicación 29: Una molécula de ácido nucleico aislada que codifica un anticuerpo que se une a ATbH e inhibe la actividad anticoagulante, en la que el anticuerpo comprende una región variable de cadena pesada que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC ID Nº 2, 4, 6, 8 y 10.
ARP140101104A 2013-03-14 2014-03-14 ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b AR095499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784590P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
AR095499A1 true AR095499A1 (es) 2015-10-21

Family

ID=50680168

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101104A AR095499A1 (es) 2013-03-14 2014-03-14 ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b

Country Status (18)

Country Link
US (4) US20140271660A1 (es)
EP (1) EP2970500A1 (es)
JP (1) JP2016519081A (es)
KR (1) KR20150127202A (es)
CN (1) CN105229033B (es)
AR (1) AR095499A1 (es)
AU (1) AU2014236198A1 (es)
BR (1) BR112015021399A2 (es)
CA (1) CA2916421A1 (es)
HK (1) HK1215261A1 (es)
MX (1) MX2015012441A (es)
PE (1) PE20160533A1 (es)
RU (1) RU2015143696A (es)
SG (1) SG11201506886TA (es)
TW (1) TW201529602A (es)
UY (1) UY35457A (es)
WO (1) WO2014153195A1 (es)
ZA (1) ZA201507628B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916421A1 (en) 2013-03-14 2014-09-25 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
US10356677B2 (en) * 2014-05-19 2019-07-16 Nokia Solutions And Networks Oy Re-establishment procedure in dual connectivity networks
DK3313879T3 (da) 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrinreceptor-antistoffer med tilpasset affinitet
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114014936A (zh) 2015-10-02 2022-02-08 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
EP3430059A1 (en) * 2016-03-18 2019-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-antithrombin single-domain antibodies and polypeptides comprising thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5578253A (en) 1978-12-11 1980-06-12 Teikoku Hormone Mfg Co Ltd Immune measurement of hito antithrombin 3
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
BE896543A (fr) 1983-04-22 1983-08-16 Wallone Region Ensembles d'anticorps monoclonaux deriges contre les proteines humaines impliquees dans la coagulation et la fibrinolyse du sang
JPH0644876B2 (ja) 1985-12-13 1994-06-15 株式会社ヤトロン 抗トロンビン・アンチトロンビン３複合体モノクローナル抗体、及びその製造方法、並びにそれを用いるトロンビン・アンチトロンビン３複合体の免疫定量法、及びそれを用いるトロンビン・アンチトロンビン３複合体の精製方法
JPH0266458A (ja) 1988-09-01 1990-03-06 Takara Shuzo Co Ltd ビトロネクチン及びビトロネクチン‐トロンビン‐アンチトロンビン３複合体の測定方法
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU628960B2 (en) 1989-04-07 1992-09-24 Teijin Limited Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
JPH0694713A (ja) 1991-07-31 1994-04-08 Masashi Funayama アンチトロンビンｉｉｉ活性の測定方法とそれを用いたアンチトロンビンｉｉｉ活性の測定キット
JPH07238099A (ja) 1994-02-25 1995-09-12 Dai Ichi Pure Chem Co Ltd モノクローナル抗体及びこれを用いる免疫学的測定法
FR2718849B1 (fr) 1994-04-14 1996-06-14 Pasteur Sanofi Diagnostics Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention.
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
JP3841364B2 (ja) 1994-10-18 2006-11-01 株式会社三菱化学ヤトロン 抗ヒトビトロネクチン・トロンビン・アンチトロンビンｉｉｉ 複合体モノクローナル抗体、ハイブリドーマ及び免疫学的測定方法
ATE403001T1 (de) 1996-05-22 2008-08-15 Viventia Biotech Inc Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
WO1997045538A1 (en) 1996-05-31 1997-12-04 Medigene Ag Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
DE60037513T2 (de) 1999-05-13 2009-02-05 GTC Biotherapeutics, Inc., Framingham Transgene hergestellte antithrombin iii und deren mutanten
JP2001321167A (ja) 2000-05-10 2001-11-20 Cosmo Research Inst モノクローナル抗体
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
JP2002316999A (ja) 2001-04-17 2002-10-31 Dai Ichi Pure Chem Co Ltd モノクローナル抗体
US20090226429A1 (en) 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
AU2003234706A1 (en) 2002-04-15 2003-11-03 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5
ATE522601T1 (de) 2002-05-31 2011-09-15 Univ Utah Res Found Varianten von antithrombin iii
EP1382615A1 (en) 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
RU2262109C2 (ru) 2002-12-30 2005-10-10 Институт биохимической физики им. Н.М. Эмануэля Российской академии наук Способ определения концентрации антитромбина iii в плазме крови
EP2184298A1 (en) 2003-03-14 2010-05-12 Wyeth a Corporation of the State of Delaware Antibodies against human IL-21 receptor and uses therefor
EP1633316A4 (en) 2003-05-06 2008-04-02 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
GB2404981A (en) 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
AU2004290017B2 (en) 2003-11-07 2012-05-03 Immunex Corporation Antibodies that bind interleukin-4 receptor
US7271245B2 (en) 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
EP1848672A4 (en) 2005-02-01 2009-11-04 Morphosys Ag BANKS AND METHODS FOR ISOLATING ANTIBODIES
ATE539764T1 (de) 2007-07-20 2012-01-15 Univ Paris Sud Xi Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen
WO2009021754A2 (en) 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
KR101529743B1 (ko) 2007-11-29 2015-06-17 그리폴스 테라퓨틱스 인코포레이티드 재조합적으로 변형된 플라스민
ES2346618B1 (es) 2008-08-14 2011-08-03 Universidad De Murcia Anticuerpo monoclonal anti antitrombina citrulinada humana y sus usos.
NO330078B1 (no) 2008-09-22 2011-02-14 Optipro As Fremgangsmåte og apparat for å overvåke slitasje i sikteduker
WO2010047830A2 (en) 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
EP3401333B1 (en) 2010-09-09 2021-05-19 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
US20140356377A1 (en) 2011-08-25 2014-12-04 Umc Utrecht Holding B.V. Compounds for use in boosting coagulation
EP2776603B1 (en) 2011-11-11 2019-03-06 SiO2 Medical Products, Inc. PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS
CA2916421A1 (en) * 2013-03-14 2014-09-25 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
JP6094713B1 (ja) 2016-06-30 2017-03-15 富士ゼロックス株式会社 定着部材、定着装置、及び画像形成装置

Also Published As

Publication number Publication date
WO2014153195A1 (en) 2014-09-25
US9908942B2 (en) 2018-03-06
BR112015021399A2 (pt) 2017-07-18
US20160024222A1 (en) 2016-01-28
TW201529602A (zh) 2015-08-01
KR20150127202A (ko) 2015-11-16
US10144784B2 (en) 2018-12-04
AU2014236198A1 (en) 2015-10-15
US20180244799A1 (en) 2018-08-30
ZA201507628B (en) 2017-11-29
JP2016519081A (ja) 2016-06-30
MX2015012441A (es) 2016-08-08
US20140271661A1 (en) 2014-09-18
SG11201506886TA (en) 2015-09-29
UY35457A (es) 2014-10-31
RU2015143696A (ru) 2017-04-19
US20140271660A1 (en) 2014-09-18
CN105229033A (zh) 2016-01-06
CA2916421A1 (en) 2014-09-25
PE20160533A1 (es) 2016-06-09
EP2970500A1 (en) 2016-01-20
CN105229033B (zh) 2019-04-23
US9593166B2 (en) 2017-03-14
HK1215261A1 (zh) 2016-08-19

Similar Documents

Publication Publication Date Title
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
AR099698A1 (es) Anticuerpos contra el c5 que tienen farmacocinética mejorada
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
AR104280A1 (es) Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
AR109882A1 (es) Anticuerpos monoclonales neutralizantes anti-tl1a
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
AR087567A1 (es) Anticuerpos anti-tie2 y usos de los mismos
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
AR102592A1 (es) Anticuerpos biespecíficos y métodos de uso en oftalmología
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ

Legal Events

Date Code Title Description
FB Suspension of granting procedure